MAPK-IN-2
Product Specifications
UNSPSC Description
MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFRWT IC50=281 nM, c-MET IC50=205 nM, B-RAFWT IC50=112 nM, and CDK4/6 IC50=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFRT790M IC50=69 nM and B-RAFV600E IC50=83 nM)[1].
Target Antigen
CDK; c-Met/HGFR; EGFR; p38 MAPK; Raf
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;JAK/STAT Signaling;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/mapk-in-2.html
Solubility
DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C1C(C#N)=C(C2=CC=C(Cl)C=C2Cl)C=C(C3=CNC4=C3C=CC=C4)N1
Molecular Weight
380.23
References & Citations
[1]Saleh MM, et al. The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6-Indolylpyridone-3-Carbonitrile derivatives. Eur J Med Chem. 2023 Nov 5;259:115675.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-155736/MAPK-IN-2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-155736/MAPK-IN-2-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6334080-01 0.2 mL
PIK3R3, CT (PIK3R3, Phosphatidylinositol 3-kinase regulatory subunit gamma, Phosphatidylinositol 3-kinase 55kD regulatory subunit gamma, p55PIK) (AP)
Ask
View Details MBS6334080-02 5x 0.2 mL
PIK3R3, CT (PIK3R3, Phosphatidylinositol 3-kinase regulatory subunit gamma, Phosphatidylinositol 3-kinase 55kD regulatory subunit gamma, p55PIK) (AP)
Ask
View Details NBP3-24339JF525 0.1 mL
Mouse Monoclonal CD74 Antibody (rCLIP/8679) [Janelia Fluor 525]
Ask
View Details